Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Leukemia, Myeloid, Acute 6Solid Tumor 2Myelodysplastic Syndromes 2Lymphoma, Non-Hodgkin 2Colorectal Neoplasms 2Urinary Bladder Neoplasms 1Unresectable Colorectal Cancer 1Triple Negative Breast Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Recurrence 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Myeloid Malignancies 1Multiple Myeloma 1Lymphoma, Large B-Cell, Diffuse 1Hematologic Neoplasms 1Carcinoma, Transitional Cell 1

Interventions

pembrolizumab 51Nivolumab 27Gemcitabine 23atezolizumab 19Cisplatin 18Carboplatin 18enfortumab vedotin 15avelumab 15Mitomycin 14Docetaxel 8Ipilimumab 7Paclitaxel 6Injections 5Cyclophosphamide 5vinflunine 4toripalimab 4tislelizumab 4lenvatinib 4fludarabine 4epacadostat 4Pemetrexed 4130-nm albumin-bound paclitaxel 4sacituzumab govitecan 3disitamab vedotin 3Rogaratinib 3Interleukin-2 3ALT-803 3vofatamab 2valrubicin 2rucaparib 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Carcinoma, Transitional Cell × magrolimab × Clear all
NCT03869190 2026-01-22

Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatments and Combinations in Patients With Urothelial Carcinoma (MORPHEUS-UC)

Hoffmann-La Roche

Phase 1/2 Completed
272 enrolled
Genitourinary

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡